Clinical Trial Search

Primary: Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 13 or Early Discontinuation — 83.5; 85.7; 6.9; -3.1 units on a scale…

Primary: Time to Relapse or an Impending Relapse — 0; 3; 1; 14 relapses

Primary: Loss of Effect Over Time — 7; 15; 6; 3 Participants

Primary: Number of Participants Demonstrating Improvement in Substance Use — 3; 3 participants

Primary: Genetic Linkage — 5.2 log (odds ratio) — p=<0.001

Primary: Error Percentage in Antisaccade Task — 22.6; 29.1 Error Percentage in Antisaccade Task — p=<0.05

Primary: Verbal Short Term Memory — 43.7; 37.9; 43.6; 40.8 t-score — p=0.90

Primary: Average Over Time of Intensity of Cannabis Use (Used to Evaluate Treatment Efficacy) — 0.02; 4.56 Joints per week — p=.088

Primary: The State Social Paranoia Scale (SSPS) — 9.72; 3.90 The change score of SSPS (pre - post) — p=0.023

Primary: Biomarkers — 287.37; 340.83; 492.33; 420.17 pg/mL

Primary: Plasticity Improvement (Change in Tone Matching Threshold) — 13.9; 5.3; 11; -0.05 log ratio

Primary: tDCS Engagement of DLPFC Activity Indexed by fMRI BOLD Imaging

Primary: Change in Auditory Hallucination Rating Scale (AHRS)Score From Baseline to Day 5 — -6.38; -8.54 units on a scale — p=0.48

Primary: Positive and Negative Symptom Improvement — 41.3; 40.3; 36.6; 37.3 score on a scale

Primary: PANSS Total — 77.9; 80 units on a scale — p=0.02

Primary: Number of Subjects With an Adverse Events in a One Year Open Label Lurasidone Study — 59 participants

Primary: Positive and Negative Syndrome Scale (PANSS) — 72.9 score on a scale

Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4 — -9.7; -17.2 Units on a scale — p=0.001

Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 26 — 68.9; 28.1 Units on a scale

Primary: End-of-session Carbon Monoxide — 62.7; 43.0 parts per million (ppm)

Primary: Change From Baseline in Neurocognitive Function as Measured by the Neurocognitive Composite Score of the Measurement and Treatment Research to Improve Cognition in…

Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 24 — 72.4; -6.9 Units on a scale

Primary: Changes in Positive Schizophrenia Symptoms — 3.21; 3.30; 3.04; 2.89 units on a scale — p=.30

Primary: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events (AEs) Leading to Study Discontinuation — 153; 77; 16; 0 Participants

Primary: Change From Baseline in PANSS Total Score at Week 6 — -19.3; -16.9; -19.6 score on a scale — p=0.886

Primary: Cognitive Performance — 76.7; 75.5; 67.2; 77.1 percentage correct of all trials

Primary: Percentage of Participants Assessed as Very Much Improved or Much Improved Based on Clinical Global Impression-Improvement (CGI-I) Scale - Intent-to-treat (ITT)…

Primary: Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Day 56 — 89.6; 92.0; -19.3; -19.8 Units on a scale — p=0.935

Primary: Change From Baseline in Dopamine Synthesis Capacity at Week 2 Using 18F-DOPA. — -0.0007; -0.0008; -0.0006; -0.0008 Kicer — p=0.0072

Primary: Number of Participants With Serious and Non-serious Adverse Events Spontaneously Reported by Subject and/or Observed by Investigator. — 0; 0; 1; 0 participants